Tocilizumab for reduction of mortality in severe COVID-19 patients: how
should we GRADE it?
- Vladimir Trkulja
Vladimir Trkulja
Department of Pharmacology, School of Medicine, University of Zagreb
Corresponding Author:vladimir.trkulja@mef.hr
Author Profile18 Nov 2021Submitted to British Journal of Clinical Pharmacology 25 Nov 2021Submission Checks Completed
25 Nov 2021Assigned to Editor
07 Dec 2021Reviewer(s) Assigned
28 Dec 2021Review(s) Completed, Editorial Evaluation Pending
20 Jan 2022Editorial Decision: Revise Minor
22 Jan 20221st Revision Received
24 Jan 2022Submission Checks Completed
24 Jan 2022Assigned to Editor
24 Jan 2022Review(s) Completed, Editorial Evaluation Pending
06 Feb 2022Editorial Decision: Accept
Jul 2022Published in British Journal of Clinical Pharmacology volume 88 issue 7 on pages 3539-3541. 10.1111/bcp.15283 
